BioSpace News Archive

Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will participate in a fireside chat hosted by LifeSci Capital on Tuesday, November 17, 2020 at 1:00 PM ET.

Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the appointment of Mary Thistle, Special Advisor for the Bill & Melinda Gates Medical Research Institute, to the Company’s Board of Directors (the “Board”).

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a manuscript detailing the study design and methodology for its global Phase 3 INNO2VATE program in Nephrology Dialysis Transplantation (NDT),

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company offering increased functionality for individuals suffering from neurological disorders and upper-limb paralysis, announced today the availability of MyoGames by Lusio, a video game platform designed to augment training and rehabilitation for MyoPro users, while being fun.

Global biotherapeutics leader CSL Behring announced a community partnership with six Urban League affiliates across the U.S., starting with the Urban League of Philadelphia.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).

Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced that a poster highlighting the ability of a Dascena machine learning algorithm to predict acute heart failure (AHF) risk in patients is being presented during the American Heart Association (AHA) Scientific Sessions, which are being held virtually from November 13-17, 2020.

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Ronald Krasnow, Esq. as Chief Operating Officer. In this newly created position, Mr. Krasnow will report to Julie Hambleton, M.D., Arch Oncology’s Interim President and Chief Executive Officer. “Ron is a legal and strategy executive with a unique breadth of e

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce topline results from the Company’s partnership with the Icahn School of Medicine at Mount Sinai, New York (“Icahn School of Medicine”)

Up to 55% of migraine patients do not have sufficient relief with currently available treatments.2 NURTEC™ ODT (rimegepant) can work quickly, returning patients to normal function in as little as one hour.